Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 Pediatric Dermatology

Holly Neale, BS\textsuperscript{a,b}, Elena B. Hawryluk, MD, PhD\textsuperscript{a,c,d,*}

KEYWORDS
• MIS-C • Pediatric dermatology • COVID-19 children • Perniosis • Pernio-like lesions

INTRODUCTION
During the coronavirus disease 2019 (COVID-19) pandemic, people of all ages are susceptible to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnoses in more than 3 million children beginning in the neonatal period have been made as of April 2021.\textsuperscript{1,2} When compared with adults, however, pediatric patients manifest with less severe respiratory sequelae and higher frequencies of no, mild, or atypical symptoms.\textsuperscript{3–6}

Reasons behind the contrasting presentation of COVID-19 in youth compared with aged individuals are multifactorial.\textsuperscript{7} Children are less likely to have predisposing factors for severe disease, such as underlying medical comorbidities\textsuperscript{8} or damaged endothelium.\textsuperscript{9} Moreover, young people demonstrate differing antibody responses to SARS-CoV-2 infection\textsuperscript{10} and possess stronger antiviral innate and adaptive immunity compared with older adults (including more cytokines, increased production of interferons,\textsuperscript{11} increased CD4\textsuperscript{+}/CD8\textsuperscript{+} T cells, and a more vigorous CD8\textsuperscript{+} T-cell response to new antigens).\textsuperscript{12} Although these inherent protections likely aid in preventing the serious respiratory sequelae of COVID-19 in most children,\textsuperscript{13} robust immune mechanisms also might contribute to alternate manifestations observed, such as cutaneous eruptions.

Lack of traditional or severe signs can heighten attention to nontraditional presentations, making dermatologic manifestations particularly relevant in children. Cutaneous signs sometimes are the predominant or only clue toward pediatric COVID-19 infection.\textsuperscript{14,15} One of the earliest exemplifications of pediatric dermatoses related to the pandemic is the acral skin eruption, known as COVID toes.\textsuperscript{16} Many children and adolescents since have presented with various acral and nonacral skin findings in connection to SARS-CoV-2 infection; cutaneous manifestations are recognized as the seventh most common extrapulmonary COVID-19 association in children.\textsuperscript{17} Greater than 8% of hospitalized COVID-19 positive pediatric patients have a cutaneous eruption,\textsuperscript{18} and dermatologic manifestations may be a component of a serious, systemic pediatric presentation, such as multisystem inflammatory syndrome in children (MIS-C). Thus, although cutaneous signs of...
COVID-19 infection often are a form of mild disease in children, it also is necessary to consider the possibility of more serious complications. Herein, the clinical presentation, demographic trends, pathophysiologic theories, implications, and management strategies for dermatologic presentations of COVID-19 are addressed with respect to MIS-C, acral eruptions, and various vascular, inflammatory, and nonspecific skin findings. Through descriptions of COVID-19 pediatric cutaneous manifestations, this article demonstrates the role of the dermatologist and importance of prompt recognition.

MULTISYSTEM INFLAMMATORY SYNDROME

- MIS-C is a serious and sometimes life-threatening response to COVID-19 infection in children, leading to organ dysfunction, shock, and often the need for intensive care and circulatory support.
- Skin and/or mucous membrane changes may be present in more than half of children affected by MIS-C and appear with various morphologies and distributions.
- Although most require intensive care, patients with MIS-C carry a good prognosis, with mortality estimated at 2%.

Definition

To date, one of the most severe pediatric consequences of COVID-19 infection is MIS-C. Initially recognized approximately 1 month after the first COVID-19 pandemic surge, MIS-C is a hyperinflammatory response to SARS-CoV-2 infection in pediatric patients that leads to dysfunction in several organs. The Centers for Disease Control and Prevention (CDC) has defined MIS-C as an individual under 21 years old with current or recent SARS-CoV-2 infection (or exposure), a fever lasting greater than 24 hours, laboratory inflammatory marker evidence, and the presence of severe illness involving greater than 2 organs (cardiac, respiratory, gastrointestinal, dermatologic, renal, hematologic, or neurologic), requiring hospital admission that cannot be explained by other illness (Fig. 1).

Demographics

Since the earliest reported cases in England,22 more than 3000 children have been affected by MIS-C, as of April 2021. A majority of children who develop MIS-C previously were healthy.24 Cases have been reported as young as 1 month old25 to 20 years old,26 with median age estimated between 5 years and 11.5 years old.20 There is a slight male predominance, and minority races/ethnicities are affected by MIS-C more commonly than non-Hispanic white children.19,24

Pathogenesis

Due to temporal emergence of MIS-C with the pandemic in addition to confirmed laboratory evidence of SARS-CoV-2 infection in 99% of cases,23 it is highly suggestive that MIS-C indeed is a consequence of COVID-19 infection. Specifically, it is thought that MIS-C is a late or postviral complication due to trends revealing a higher likelihood of SARS-CoV-2 antibody positivity compared with viral RNA detection.27–30 Children who report milder viral symptoms before MIS-C onset support the notion of MIS-C being a later sequela; the median time to onset has been reported at 25 days.24

Although the exact mechanisms are not yet understood, MIS-C is described as the result of a cytokine storm in response to COVID-19 infection.31 Pathogenesis theories include the role of an overly robust pediatric innate and/or cellular immune response,27 superantigen region on the SARS-CoV-2 spike protein,32,33 and immune-complex development from viral antigens (type III hypersensitivity)34 inciting strong cytokine cascade. A pediatric biorepository has been established with one main goal to better understand the complex immunologic mechanisms underpinning MIS-C.35

Cutaneous Presentation

MIS-C demonstrates a wide spectrum of cutaneous associations (Fig. 2). Mucocutaneous findings are a component of MIS-C in 50% to 83% of children,19,24,29,36,37 which are variable and polymorphic (Table 1). Purpuric, targetoid, erythematous, retiform, reticular, livedoid, urticarial, scarlatiniform, papular, macular, maculopapular, desquamative, erythema multiforme (EM)-like, and morbilliform exanthes have been described.37–41 Eruptions may be generalized or localized, such as to the trunk, face, periorbital area, extremities, or diaper area.29,38,40,41 In 1 series of 7 MIS-C patients with cutaneous findings, 57% had lesions described as urticarial-like plaques, all had involvement of the lower extremities, and 29% experienced mild pruritis.37 The hands and feet frequently are a site of cutaneous symptoms; findings include erythema, swelling (edema), and desquamation.28,38–40 Mucositis in the forms of papillitis of the tongue (strawberry tongue),28,41 cheilitis (lips appearing erythematous, swollen, dry, or cracked/
fissured,28,39,40,42 and/or conjunctivitis 29,41 frequently are observed.

Although some investigations have found no correlation between mucocutaneous findings and worsened disease severity,29,41 1 study reported that mucocutaneous signs were a risk factor for intensive care unit admission, more severe inflammatory marker derangement (C-reactive protein

Fig. 1. CDC diagnostic criteria for MIS-C. An individual aged less than 21 with SARS-CoV-2 (confirmed or suspected within prior 4 weeks), a fever for greater than or equal to 24 hours, involvement of at least 2 organ systems (+gastrointestinal, hematologic, neurologic, dermatologic, respiratory, cardiovascular, or renal), laboratory evidence of inflammation, severity requiring hospitalization, and no other explanation must be present.21 (*Laboratory markers of inflammation include but are not limited to elevations in fibrinogen, ferritin, D-dimer, erythrocyte sedimentation rate, C-reactive protein, procalcitonin, interleukin-6, neutrophils, lactic acid dehydrogenase, and/or low albumin or lymphocytes21; examples of hepatobiliary markers: AST/ALT119; examples of hematologic markers: neutrophil, lymphocytes, platelets, hemoglobin 119; examples of cardiac markers: troponin, brain natriuretic proenzyme21; and examples of renal markers: creatinine,119 blood urea nitrogen, electrolytes.)

| *Laboratory Inflammatory Evidence |
|-----------------------------------|
| ↑ D-dimer                         |
| ↑ Procalcitonin                   |
| ↑ Fibrinogen                      |
| ↑ Ferritin                        |
| ↑ Neutrophilia                    |
| ↑ Elevated lactate dehydrogenase  |
| ↑ Erythrocyte Sedimentation Rate  |
| ↑ C-reactive Protein              |
| ↑ Interleukin-6                   |
| ↓ Lymphopenia                     |
| ↓ Albumin                         |

| *Organ System | Examples of involvement |
|---------------|-------------------------|
| Gastrointestinal | Abdominal pain, diarrhea, nausea, vomiting, abnormal hepatobiliary markers |
| Hematologic | Fever, myalgias, lymphadenopathy, fatigue, abnormal blood counts |
| Neurologic | Headache, irritability, altered mental status, dizziness |
| Dermatologic | Cutaneous eruption, conjunctivitis, edema, mucositis |
| Respiratory | Dyspnea, upper respiratory infection-like signs, cough, wheezing, respiratory failure, pulmonary infiltrates |
| Cardiovascular | Shock, chest pain, myocarditis, coronary artery dilatation/aneurysm, elevated cardiac enzyme markers |
| Renal | Acute kidney injury |

**Suspected or confirmed COVID-19?**

- Yes

**Fever ≥38 degrees Celsius for ≥24 h?**

- Yes

**Hospitalization requirement?**

- Yes

**Laboratory evidence of inflammation?**

- Yes

**Involvement of ≥2 organ systems?**

- Yes

**MIS-C criteria met by CDC definition**
[CRP], D-dimer, and lymphopenia), and poor presentation with severe tachycardia. \(^{43}\) Mucocutaneous manifestations typically resolve with treatment of underlying MIS-C. \(^{37}\) Importantly, mucocutaneous findings associated with fever in a child are nonspecific, and in the setting of negative COVID-19 testing can pose a diagnostic challenge.

**Extracutaneous Presentation**

In addition to dermatologic presentation, awareness of the most common extra-mucocutaneous findings of MIS-C is necessary when evaluating a child for skin eruption in the COVID-19 pandemic. Fever, a critical component of the MIS-C diagnosis, \(^{21}\) usually precedes mucocutaneous findings but can occur after or during acute presentation. \(^{29}\) Other vital sign changes in the form of tachycardia, tachypnea, and hypotension are presenting signs in more than three-quarters of affected children. \(^{26,36}\)

The gastrointestinal system is the most common organ system involved in MIS-C, and signs in the form of abdominal pain, vomiting, and/or diarrhea are noted in 80% to 92% of cases. \(^{24,26}\) Respiratory symptoms, such as dyspnea, upper respiratory infection-like signs, and respiratory insufficiency, are observed in 21% to 70% of cases. \(^{24,26,29}\) Cardiovascular involvement may present clinically as hypotension, shock, or, less commonly, chest pain. \(^{44,45}\) Neurologic and hematologic abnormalities manifest with various signs and symptoms, such as headache, dizziness, mental status change, fatigue, lymphadenopathy, lethargy, and myalgias. \(^{26,44}\)

With accumulating cases, an analysis of 570 children reported to the CDC allowed the identification of 3 distinct subgroups based on patient underlying features. Rash and mucocutaneous findings were prominent in a group of “MIS-C overlapping with Kawasaki disease (KD),” that was characterized by younger patients (median age 6 years) and lower frequency of myocardial dysfunction or shock. In contrast, the other groups represented “MIS-C without overlap with acute COVID-19 or KD” (median age 9 years) with prominent cardiovascular and gastrointestinal symptoms, and “MIS-C overlapping with severe acute COVID-19” (median age 10 years) with prominent respiratory symptoms. \(^{30,46}\)

**Work-up**

The CDC recommended laboratory work-up for suspected MIS-C includes a SARS-CoV-2 reverse-transcriptase polymerase chain reaction (RT-PCR) test and serologic testing (prior to treatment initiation) when available. \(^{21}\) Inflammatory marker elevation is a critical component of

---

*Fig. 2. Cutaneous eruptions in patients with MIS-C. (A) An erythematous plaque of the neck on a 7-year-old girl. (B) A 12-year-old boy with a maculopapular eruption of the trunk and extremities as well as (C) erythema of the palms. (From Fludiona Naka, Laura Melnick, Mark Gorelik, Kimberly D. Morel, A dermatologic perspective on multisystem inflammatory syndrome in children, Clinics in Dermatology, 2020.)*
Diagnosis, and markers to test include erythrocyte sedimentation rate, CRP, fibrinogen, procalcitonin, ferritin, lactic acid dehydrogenase, D-dimer, interleukin-6, and albumin. Additionally, a complete blood cell count to look for lymphocytopenia, neutrophilia, and/or thrombocytopenia is warranted, because hematologic abnormalities are present in the majority cases. A comprehensive metabolic panel may reveal end organ impacts, such as acute kidney injury or abnormal hepatobiliary markers.

Usually, children receive cardiac work-up, including cardiac enzyme biomarkers, brain natriuretic peptide, echocardiogram, and/or electrocardiogram due to a known relationship between MIS-C and myocarditis, cardiac dysfunction, and/or coronary artery dilation/aneurysm. When clinically warranted, radiologic assessment of the chest or abdomen is performed and may reveal further systemic effects, such as pulmonary infiltrates, lymphadenopathy, pleural effusion, hepatosplenomegaly, ascites, or ileitis.

### Differential Diagnosis

Many features of MIS-C presentation resemble KD in children, making KD a top differential diagnosis. Findings, such as high fever, conjunctivitis, lymphadenopathy, cheilitis, skin rash, myocarditis, and coronary artery aneurysms occur in both KD and MIS-C. Although the features of MIS-C overlap with KD and incomplete KD, many children do not meet the full diagnostic criteria and distinguishing demographic trends in age and geography are apparent between the 2 diseases (Table 2).

A severe COVID-19 infection (without meeting criterion for MIS-C) also is possible. A retrospective comparison of MIS-C versus severe COVID-19 in 1116 hospitalized patients ages 21 and under revealed MIS-C patients presented more frequently with mucocutaneous signs than those with severe COVID-19. MIS-C cases showed greater laboratory inflammation, and complications were more likely to involve the cardiac system.

In addition to KD, the differential for MIS-C includes systemic illnesses, such as macrophage-activation syndrome, toxic-shock syndrome, bacterial sepsis, and scarlet fever. Depending on the clinical picture, drug hypersensitivity, vasculitis, or other viral infections may be considered.

### Prognosis and Management

MIS-C is a serious complication of COVID-19 in children, requiring intensive care unit admission in up to 80% of cases and often supportive care, including vasopressors, fluids, and/or mechanical ventilation. Treatment includes intravenous immunoglobulin and corticosteroids; many patients also receive anticoagulants and/or antiplatelet agents. Medications, such as antivirals, cytokine blockers, and various immunomodulatory agents, have been used. Few children may improve without any immunomodulatory therapy. The median hospital stay is approximately 1 week and a large majority of MIS-C patients enter remission. There have been reports of death, however, due to MIS-C following COVID-19 infection; mortality is estimated at 2%.

The post-hospitalization sequelae of MIS-C are just beginning to be appreciated. Coronary artery abnormalities were identified in a notable percentage of patients in all 3 clinical presentations/subgroups of MIS-C, described previously, ranging from 16% to 21%, which has an impact on patient return to baseline activities. It has been observed that a majority of MIS-C patients with severe cardiac complications recover within 1 months to 3 months. Although impacts on hair are not robustly documented in pediatric patients...
with MIS-C, there are reports of alopecia areata and telogen effluvium, which may be related to the infection, a postinfectious sequelae of disease, or associated stress.51 Although skin findings are nonspecific and non-diagnostic, dermatologists must be aware of MIS-C and potential downstream sequelae. Children who present with a new skin eruption, swollen extremities, or mucous membrane changes during the COVID-19 era benefit from a full review of systems, vital signs, and in-person examination. If a presentation is suspicious for MIS-C but the patient otherwise is stable, it is appropriate to obtain laboratory testing to assess for COVID-19 infection and markers of inflammation for signs of multi-organ dysfunction, and/or consult subspecialists.52 Stable patients with cutaneous eruption of unknown etiology during the pandemic may be counseled to monitor for development of accompanying signs of MIS-C. Severely ill children must be evaluated by emergency/critical care for immediate further work-up and management.

**PERNIO (CHILBLAINS)-LIKE LESIONS**

- Pernio-like lesions are an inflammatory response to COVID-19 resulting in purpuric and erythematous acral cutaneous surfaces.
- Children and young adults are more likely to manifest with pernio-like lesions than older adults.
- Pernio-like lesions typically are self-limiting with excellent prognosis, although recurrent skin sequelae are being appreciated.

**Evolution of COVID-19 Toes**

Traditional pernio, also called chilblains, is an inflammatory reaction of the superficial vasculature on acral cutaneous surfaces (fingers, toes, nose, and ears) that often is idiopathic and triggered by cool and/or damp temperatures (primary pernio) or, less commonly, is due to an underlying autoimmune or systemic inflammatory disease (secondary pernio).53 Outside of the COVID-19 era, pernio is considered a relatively uncommon disease54; 1 study reported only 8 pediatric cases in 10 years,55 although many consider this reaction to be clinically identified and readily managed with supportive care. Following the start of the COVID-19 pandemic, thousands of children and young adults with no prior history of acral skin changes began to develop asymptomatic, painful, and/or pruritic lesions with striking resemblance to pernio: erythematous, purpuric papules, and macules.

### Table 2

**Kawasaki disease compared with multisystemic inflammatory syndrome in children**

| Demographics                  | Kawasaki Disease                                                                 | Multisystem Inflammatory Syndrome in Children44 |
|-------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------|
| **Age**                       | Younger children (90% of cases under age 5)110                                  | Mean age 9 years old                          |
| **Geography**                 | More common in Asia (Japan, South Korea, and Taiwan)111                        | Majority of reports from the US and Europe     |
| **Race/ethnicity**            | Most common in Asian and Pacific Islanders112                                    | >65% of cases in Hispanic/Latino or non-Hispanic black children |
| **Gender**                    | Male predominance110                                                             | Slight male predominance                       |
| Clinical signs                |                                                                                  |                                               |
| **Fever**                     | Unexplained fever lasting $\geq 5$ d must be present112                         | Fever lasting $>24$ h must be present          |
| **Conjunctivitis**            | 4 of 5 are part of diagnostic criteria (or 3 of 5 for incomplete KD)112         | $<50\%$ meet criteria for KD                  |
| Oral mucosal change           |                                                                                  |                                               |
| Distal extremity changes      |                                                                                  |                                               |
| Skin rash                     |                                                                                  |                                               |
| Cervical lymphadenopathy      |                                                                                  |                                               |
| **Gastrointestinal involvement** | Present in 61%113                                                              | Present in 87%                                |
| **Respiratory involvement**   | Slightly less common Present in 35%113                                           | Slightly more common Present in 41%           |
| **Cardiovascular shock**      | Less common Present in $<10\%$114                                               | More common Present in 66%                    |

### Table 2

**Kawasaki disease compared with multisystemic inflammatory syndrome in children**

| Demographics                  | Kawasaki Disease                                                                 | Multisystem Inflammatory Syndrome in Children44 |
|-------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------|
| **Age**                       | Younger children (90% of cases under age 5)110                                  | Mean age 9 years old                          |
| **Geography**                 | More common in Asia (Japan, South Korea, and Taiwan)111                        | Majority of reports from the US and Europe     |
| **Race/ethnicity**            | Most common in Asian and Pacific Islanders112                                    | >65% of cases in Hispanic/Latino or non-Hispanic black children |
| **Gender**                    | Male predominance110                                                             | Slight male predominance                       |
| Clinical signs                |                                                                                  |                                               |
| **Fever**                     | Unexplained fever lasting $\geq 5$ d must be present112                         | Fever lasting $>24$ h must be present          |
| **Conjunctivitis**            | 4 of 5 are part of diagnostic criteria (or 3 of 5 for incomplete KD)112         | $<50\%$ meet criteria for KD                  |
| Oral mucosal change           |                                                                                  |                                               |
| Distal extremity changes      |                                                                                  |                                               |
| Skin rash                     |                                                                                  |                                               |
| Cervical lymphadenopathy      |                                                                                  |                                               |
| **Gastrointestinal involvement** | Present in 61%113                                                              | Present in 87%                                |
| **Respiratory involvement**   | Slightly less common Present in 35%113                                           | Slightly more common Present in 41%           |
| **Cardiovascular shock**      | Less common Present in $<10\%$114                                               | More common Present in 66%                    |
affecting the toes, feet, fingers, and hands (Fig. 3 morphologies are discussed in further detail in Ritesh Agnihothri and Lindy P. Fox’s article, “Clinical Patterns and Morphology of COVID-19 Dermatology,” in this issue). The temporal relationship of increased pernio-like cases coinciding with the pandemic alluded to a possible relationship. Thus, the terms, COVID toes and COVID fingers, were coined, and pernio-like lesions since have become the cutaneous manifestation in confirmed or suspected COVID-19 infected individuals across the globe reported most frequently.56

**Why Youth?**

Younger, healthy people tend to present with pernio-like lesions at higher frequencies than older adults.57 The median age of pernio-like lesions is the mid-20s to late 20s,56,58 and 29% of those with pernio-like lesions are children or adolescents.59 Leading theories aid in explaining the demographical trend toward healthy youth. The immune system of younger individuals has higher amounts of interferon compared with older adults,11 which provides innate immunity against viruses.60 It is known that constitutive type 1 interferon responses lead to autoinflammatory manifestations, including chilblains.61 Thus, it is possible that when infected with COVID-19, healthy children and young adults mount a strong interferon response, clearing the virus,62 and subsequently develop pernio-like lesions as a delayed consequence of inflammation,63,64

Supporting this theory, it has been found that individuals with pernio-like lesions respond with significantly higher blood levels of interferon alpha when stimulated with immune ligands compared with patients with acute COVID-19 infection.65 Higher rates of antibody test positivity compared with rates of RNA detection in individuals with pernio-like lesions,65 in addition to the tendency for delayed presentation of lesions in relation to extracutaneous symptoms (Table 3),56,59 provide additional support of pernio-like lesions as a postviral manifestation of COVID-19 infection. Biopsies of pernio-like lesions offer evidence of a primarily inflammatory process.66

![Fig. 3. Pernio-like lesions in children.](image-url)

(A) A child with purpuric papules on the 1st, 2nd, 4th, and 5th right digits and 2nd proximal left digit and (B) Digits on the same child appearing with increased erythema. (C) Right toes of a child appearing with pink and dusky papules and plaques, also involving (D) the child's left digits.
Relationship to COVID-19

SARS-CoV-2 nasopharyngeal RNA and/or serologic results often fail to demonstrate COVID-19 infection in many cohorts of individuals with pernio-like lesions, leading to theories that the increase in cases may be coincidental, due to patient/provider/media awareness (confirmation bias), or a result of pandemic lifestyle changes (such as walking barefoot at home more often). Lack of laboratory positivity, however, may speak more to testing nuances rather than lack of true infection. Cleared infections; failure to look for IgG, IgM, and/or IgA antibodies in serologic testing; and improper timing of testing in relation to disease (ie, the window between cleared infection and detectable antibodies) are potential reasons why viral testing may read negative following COVID-19 infection. For example, given the theory that pernio-like lesions are a post-viral manifestation, for a child presenting with pernio-like lesions 10 days after a mild cough, RNA testing would be negative if the infection was cleared (the median time to undetectable RNA is 14 days, meaning 50% of individuals test negative before then), and antibodies may not yet be detectable (average length to mount response is 1–3 weeks), thus, possible that neither test would be positive. In separate analysis of 906 reported cases of confirmed or suspected COVID-19-associated skin manifestations, COVID-19 tests were more likely to be positive if performed earlier in the disease course, and some negative tests were resulted from patients whose skin biopsies demonstrated SARS-CoV-2 RNA. Mounting evidence supports that a negative test does not necessarily rule out an association of pernio skin lesions with COVID-19, and optimal testing times remain an area of ongoing research.

Although it is possible that select patients manifest idiopathic pernio, the dramatic surge in cases (including in temperate climates), and clustering in families and close contacts, in addition to emerging evidence from larger cohorts, support a connection between pernio-like lesions cases and COVID-19. Of patients with pernio-like lesions during the pandemic, 72% have a suspected COVID-19 infection, and up to 30% of those with serologic testing have antibodies to SARS-CoV-2 (compared with <10% in the general US population). In a series of 7 pediatric cases, COVID-19 viral particles were observed in endothelial cells using electron microscopy of biopsied pernio-like lesions. With time, more readily available COVID-19 tests, and emerging data, it is anticipated that the relationship between the pandemic and pernio-like lesions will become more clear.

Pediatric Outcomes and Management

It is overall reassuring that regardless of etiology, pernio-like lesions usually are self-limited. The lesions and associated symptoms often last 1 week to 3 weeks, although, in some patients, persistence or recurrence may occur. First-line management is observation; topical corticosteroids, topical antibiotics, and nonsteroidal anti-inflammatory agents may be useful for acute inflammation. Some patients with increased pain and symptoms require additional pain management, and topical anesthetics and

| Lesion Location | Lesion Color | Primary Lesion Morphology | Secondary Lesion Features | Associated Symptoms | Extracutaneous Symptoms |
|----------------|-------------|---------------------------|--------------------------|---------------------|------------------------|
| Toes*           | Red         | Papules                   | Edema                    | None                | Fever                  |
| Feet            | Purple      | Macules                   | Erosion                  | Pruritus            | Cough                  |
| Ankles          | Brown       | Vesicles                  | Crust                    | Pain                | Sore throat            |
| Fingers         | Red-blush   | Bullae                    |                          |                     | Nasal congestion       |
| Hands           | Gray        | Patches                   |                          |                     | Rhinorrhea             |

a Including nail involvement.
b If extracutaneous signs are present, they precede cutaneous findings more than half the time.

Table 3
Clinical presentation of pernio-like lesions in children

| Lesion Location | Lesion Color | Primary Lesion Morphology | Secondary Lesion Features | Associated Symptoms | Extracutaneous Symptoms |
|----------------|-------------|---------------------------|--------------------------|---------------------|------------------------|
| Toes*         | Red         | Papules                   | Edema                    | None                | Fever                  |
| Feet          | Purple      | Macules                   | Erosion                  | Pruritus            | Cough                  |
| Ankles        | Brown       | Vesicles                  | Crust                    | Pain                | Sore throat            |
| Fingers       | Red-blush   | Bullae                    |                          |                     | Nasal congestion       |
| Hands         | Gray        | Patches                   |                          |                     | Rhinorrhea             |

a Including nail involvement.
b If extracutaneous signs are present, they precede cutaneous findings more than half the time.
analgesics, such as topical gabapentin, diclofenac, ketamine, JAK inhibitors, lidocaine patches, and ointment are reasonable choices. The long-term outcomes and recurrence rate of lesions will become apparent with time. With the temporal second wave of COVID-19 cases, there has been another increase in reported cases of pernio-like lesions.85

Clinical judgment should be used in the decision to test children for SARS-CoV-2 with consideration to timing from symptoms and pretest probability. Previously healthy children with no history of acral cutaneous disease and lack of overt risk factors for traditional pernio may benefit from RT-PCR testing if they are presenting during the COVID-19 era, particularly if they are evaluated promptly upon lesion onset.

NONSPECIFIC COVID-19 DERMATOSES

- Cutaneous eruptions can be a sole presenting sign of COVID-19, be accompanied by mild extracutaneous disease, or be seen in hospitalized COVID-19 children.
- Various inflammatory, vascular, and nonspecific cutaneous morphologies have been described.

In addition to the well-reported cases of MIS-C and pernio-like lesions in children, various other cutaneous eruptions have been reported. Table 4 summarizes the different skin findings by etiology that may be related to COVID-19 infection in pediatric patients.

**Nonperniotic Acral Cutaneous Eruptions**

Some acral manifestations overlap or coexist with pernio-like lesions and are a matter of subtle and/or subjective classification. For example, EM-like lesions have been found on the acral surfaces of children with pernio-like lesions86 and may present with purpuric morphology.87 The EM-like pattern of acral eruptions are distinguished from pernio-like lesions as round, coalescing erythematous macules and vesicles, observed more frequently in younger children.88 Similarly, ecchymotic eruptions of the toes and feet are reported with a distinct description from pernio-like lesions in children: petechial lesions on the sole, plantar singular toes, and/or heels.89

In addition to ecchymotic patterns, other vascular morphologies on the acral surfaces, like reticulated purpura of the soles of an infant90 and acrocyanosis/livedo reticularis of the extremities in children and adolescents,91 are thought to be late SARS-CoV-2 manifestations. Immunohistochemical positivity for SARS-CoV-2 has been found in EM-like, reticulated purpura, and perniotic-like acral lesions.86,90 Young individuals with such acral manifestations tend to have an uncomplicated disease course and excellent outcomes.

**Nonacral Cutaneous Eruptions**

Nonacral surfaces also are involved in cutaneous eruptions related to COVID-19 infection in children. Some manifestations that are observed in COVID-positive adults, such as erythematous, vesicular, or urticarial exanthems,92 also can present in infants and children with suspected or confirmed SARS-CoV-2 infection.15,93–95 Petechiae, which are associated with several other viral illness in children,96 have been observed in 1% to 2% of hospitalized COVID-19 positive children and may be widespread or localized.14 Case reports of children with COVID-19 further demonstrate the various forms of potential mucocutaneous changes, such as erythematous and purpuric macules on the face,97 swelling and papillitis of the tongue,98 vesicular oral eruption,99 a roseola-like rash,100 and a puritic maculopapular rash.100 These case reports do not support causality between COVID-19 and cutaneous eruptions, because there are many potential causes for exanthems in children. The virus has been further implicated, however, by its demonstration in biopsy tissue from various eruptions, including patients with EM86 and purpuric and livedoid eruptions.90

Although most cases of young individuals with cutaneous manifestations have a mild and uncomplicated disease course, some case reports demonstrate more serious forms of disease. MIS-C, as discussed previously, is one such

| Acral | Nonacral |
|-------|----------|
| Pernio-like lesions59 | Urticaria95 |
| EM-like lesions | Erythematous patches118 |
| Plantar papules14 | EM-like lesions86 |
| Retiform purpura41 | Vesicles/papulovesicles15 |
| Ecchymotic-like lesions89 | Herpetiform oral eruption99 |
| Livedo reticularis91 | Roseola-like rash100 |
| MIS-C findings (see Table 1) | Maculopapular rash100 |
| | Macular eruption14,98 |
| | Lingual papillitis97 |
| | Eccrine hidradenitis93 |
| | Erythema nodosum93 |
| | Petechiae14 |
| | Purpura97 |
| | MIS-C findings (see Table 1) |
example. Other examples in previously healthy COVID-positive children include that of a neonate with mottling skin rash and respiratory distress requiring neonatal intensive care\textsuperscript{101} and a 12-year-old girl with nonspecific skin rash, fever, and headache who went on to develop respiratory failure and was found to have encephalomyelitis.\textsuperscript{102} Despite acute systemic presentations, both of these patients improved by hospital discharge.

**SUMMARY**

The COVID-19 era has brought many advances to the understanding of interplay between viral disease, the pediatric immune system, and the skin. Evolving understanding of the mechanisms of MIS-C and pernio demonstrate the unique ways the young immune system operates; although likely protective from the traditional COVID-19 consequences like severe respiratory deterioration, the immune profile of younger individuals may holster a role in delayed inflammatory cutaneous presentations.

Although many cutaneous eruptions in children during the COVID-19 pandemic may not be related directly to infection, the possibility is an important consideration, particularly for patients with risk factors and/or highly impacted communities. Because children often present with no or mild symptoms, dermatologic manifestations of COVID-19 may be presenting signs,\textsuperscript{14} serving as a subtle clue toward the highly contagious infection. Even in the absence of more classic signs of COVID-19 like respiratory symptoms, children with COVID-19 still may spread the virus and infect others who are susceptible to a more severe disease course.\textsuperscript{103} Thus, dermatologists have an important role in containing the pandemic by appropriately counseling patients and testing for acute infection if indicated. Appropriate social distancing, mask-wearing, and hand-washing should be encouraged in children during the pandemic, especially those with risk factors, regardless of the presence or absence of extracutaneous symptoms.

Whereas some pediatric dermatologic manifestations of SARS-CoV-2, such as the polymorphous rash, mucositis, and conjunctivitis seen in MIS-C, may serve a clue toward serious sequelae, a majority of cutaneous eruptions in relation to the pandemic are benign. Despite the continually evolving understanding of COVID-19 and its potential manifestations, cutaneous eruptions fortunately most often are self-limited and not associated with poor outcomes; some studies even report children with skin rashes have a better prognosis than children with COVID-19 and no rash.\textsuperscript{41} With ongoing cases and data reports, the interaction between COVID-19 and the skin in pediatric patients will become better understood. Beyond the dermatologic manifestations of COVID-19 in the pediatric population, children and adolescents face numerous consequences of the pandemic and some are only starting to be appreciated, ranging from physical impacts, such as obesity associated with changes in diet and activity or progression of myopia during home confinement to a wide range of psychosocial consequences of school closures and home/health stressors.\textsuperscript{104}

As new, potentially more contagious, strains of COVID-19 arise, such as the B.1.1.7 variant, there has been concern for how this has an impact on the pediatric population. From February 2021 to April 2021, there was more than double the frequency of pediatric cases (all age groups) in Michigan,\textsuperscript{105} with several other states following similar trends.\textsuperscript{106} Although these rises coincide with the emergence of new variants, there is no evidence that new variants preferentially infect children.\textsuperscript{107} It is likely that such increases in pediatric cases reflect vaccination and social trends. Currently (as of April 2021), the 2-dose mRNA Pfizer-BioNTech vaccine is approved in children 16 years and older, and clinical trials are under way for younger populations.\textsuperscript{108} As schools open and sporting activities resume, it is important to counsel pediatric patients on appropriate social distancing measures, regardless of vaccination status.

**CLINICS CARE POINTS**

- A thorough skin exam in children suspected to have COVID-19 may be useful in identifying cutaneous manifestations.
- Clinical judgment must be used when deciding to test a child with new cutaneous findings for COVID-19 based on pre-test probability and test availability.
- It can be challenging to ascertain causality between cutaneous eruptions and COVID-19 infection, thus children should be encouraged to practice social distancing and good hygiene.
- The skin and mucous membranes can provide clues and/or be part of the diagnostic criteria for the serious pediatric complication of MIS-C.
• Children suspected to have MIS-C should seek emergency care.
• Most cutaneous manifestations of COVID-19, such as pernio-like lesions and non-specific eruptions limited to the skin, are self-limited.

REFERENCES

1. Children and COVID-19: State-Level Data Report. Available at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. Accessed January 27, 2021.

2. Xiong Y, Zhang Q, Zhao L, et al. Clinical and imaging features of COVID-19 in a neonate. Chest 2020;158(1):e5–7.

3. Assaker R, Colas AE, Julien-Marsollier F, et al. Presenting symptoms of COVID-19 in children: a meta-analysis of published studies. Br J Anaesth 2020;125(3):e330–2.

4. Poline J, Gaschignard J, Leblanc C, et al. Systematic severe acute respiratory syndrome coronavirus 2 screening at hospital admission in children: a French prospective multicenter study. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa1044.

5. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382(17):1663–5.

6. Dong Y, Mo X, Hu Y. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. J Pediatr Cit 2020. https://doi.org/10.1542/peds.2020-0702.

7. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child 2020. https://doi.org/10.1136/archdischild-2020-320338.

8. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.

9. Celermaier DS, Sorensen KE, Spiegelhalter DJ, et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994;24(2):471–6.

10. Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol 2021;22(1):25–31.

11. Metcalf TU, Cubas RA, Ghneim K, et al. Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell 2015;14(3):421–32.

12. Carr EJ, Dooley J, Garcia-Perez JE, et al. The cellular composition of the human immune system is shaped by age and cohabitation. Nat Immunol 2016;17(4):461–8.

13. Rao VUS, Arakeri G, Subash A, et al. COVID-19: Loss of bridging between innate and adaptive immunity? Med Hypotheses 2020;144:109861.

14. Klimach A, Evans J, Stevens J, et al. Rash as a presenting complaint in a child with COVID-19. Pediatr Dermatol 2020;37(5):966–7.

15. Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue? Pediatr Dermatol 2020;37(3):435–6.

16. Mazzotta F, Troccoli T. Acute acro-ischemia in the child at the time of COVID-19. Eur J Pediatric Dermatol. Vol 30.; 2020. doi:10.26326/2281-9649.30.2.2102.

17. Poupa PA, Mendonça TSC, Oliveira EA, et al. Extrapulmonary manifestations of COVID-19 in children: a comprehensive review and pathophysiological considerations. J Pediatr (Rio J) 2020. https://doi.org/10.1016/j.jped.2020.08.007.

18. Kilani MM, Odoh MM, Shalabi M, et al. Clinical and laboratory characteristics of SARS-CoV2-infected paediatric patients in Jordan: serial RT-PCR testing until discharge. Paediatr Int Child Health 2020. https://doi.org/10.1080/20469047.2020.1804733.

19. Felsenstein S, Willis E, Lythgoe H, et al. Presentation, treatment response and short-term outcomes in paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS). J Clin Med 2020;9(10):3293.

20. McMurray JC, May JW, Cunningham MW, et al. Multisystem inflammatory syndrome in children (MIS-C), a post-viral myocarditis and systemic vasculitis—A critical review of its pathogenesis and treatment. Front Pediatr 2020;8. https://doi.org/10.3389/fped.2020.626182.

21. Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) | CDC. Available at: https://www.cdc.gov/mis-c/hcp/. Accessed January 16, 2021.

22. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;396(10237):1607–8.

23. Health department-reported cases of multisystem inflammatory syndrome in children (MIS-C) in the United States/CDC. Available at: https://www.cdc.gov/mis-c/cases/index.html. Accessed February 26, 2021.

24. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020;383(4):334–46.

25. Lee PY, Day-Lewis M, Henderson LA, et al. Distinct clinical and immunological features of SARS-CoV-2–induced multisystem inflammatory syndrome in children. J Clin Invest 2020;130(11):5942–50.
26. Dufort EM, Kourmans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York state. N Engl J Med 2020;383(4):347–58.
27. Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune responses. J Pediatr 2020;227:45–52.e5.
28. Licciardi F, Prucchini G, Denina M, et al. SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: A novel COVID phenotype in children. Pediatrics 2020;146(2). https://doi.org/10.1542/peds.2020-1711.
29. Young TK, Shaw KS, Shah JK, et al. Mucocutaneous manifestations of multisystem inflammatory syndrome in children during the COVID-19 Pandemic. JAMA Dermatol 2021;157(2):207–12.
30. Godfred-Cato S, Bryant B, Leung J, et al. COVID-19-associated multisystem inflammatory syndrome in children — United States, March–July 2020. MMWR Morb Mortal Wkly Rep 2020;69(32):1074–80.
31. Rowley AH, Shulman ST, Ardit M. Immune pathogenesis of COVID-19–related multisystem inflammatory syndrome in children. J Clin Invest 2020;130(11):5619–21.
32. Multisystem inflammatory syndrome in children in the United States. N Engl J Med 2020;383(18):1793–6.
33. Cheng MH, Zhang S, Porritt RA, et al. An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations. bioRxiv 2020. https://doi.org/10.1101/2020.05.21.109272.
34. Roe K. A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms. Inflammopharmacology 2020;28(5):1219–22.
35. Lima R, Gootkind EF, De La Flor D, et al. Establishment of a pediatric COVID-19 biorepository: Unique considerations and opportunities for studying the impact of the COVID-19 pandemic on children. BMC Med Res Methodol 2020;20(1). https://doi.org/10.1186/s12874-020-01110-y.
36. Grimaud M, Starck J, Levy M, et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care 2020;10(1). https://doi.org/10.1186/s13613-020-00690-8.
37. Blatz AM, Oboite M, Chiotos K, et al. Cutaneous findings in SARS-CoV-2-associated multisystem inflammatory disease in children. Open Forum Infect Dis 2021;8(3). https://doi.org/10.1093/ofid/ofab074.
38. Dolinger MT, Person H, Smith R, et al. Pediatric croup disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab. J Pediatr Gastroenterol Nutr 2020;71(2):153–5.
39. Yozgat CY, Uzuner S, Bursal Duramaz B, et al. Dermatological manifestation of pediatrics multisystem inflammatory syndrome associated with COVID-19 in a 3-year-old girl. Dermatol Ther 2020;33(4). https://doi.org/10.1111/dth.13770.
40. Mazori DR, Derrick KM, Kapoor U, et al. Perineal desquamation: An early sign of the Kawasaki disease phenotype of MIS-C. Pediatr Dermatol 2020; pde:14462. https://doi.org/10.1111/pde.14462.
41. Rekhtman S, Tannenbaum R, Strunk A, et al. Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children. J Am Acad Dermatol 2020;84(2):408–14.
42. Al Ameer HH, AlKadhem SM, Busaleh F, et al. Multisystem inflammatory syndrome in children temporally related to COVID-19: A case report from Saudi Arabia. Cureus 2020;12(9). https://doi.org/10.7759/cureus.10589.
43. Andina-Martinez D, Nieto-Moro M, Alonso-Cadenas JA, et al. Mucocutaneous manifestations in hospitalized children with COVID-19. J Am Acad Dermatol 2021. https://doi.org/10.1016/j.jaad.2021.03.083.
44. Yasuhara J, Watanabe K, Takagi H, et al. COVID-19 and multisystem inflammatory syndrome in children: A systematic review and meta-analysis. Pediatr Pulmonol 2021;ppul:25245.
45. Nathan N, Prevost B, Sileo C, et al. The wide spectrum of COVID-19 clinical presentation in children. J Clin Med 2020;9(9):2950.
46. Morris SB, Belay E, Levin M, et al. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Center for Disease Control and Prevention; 2020. Available at: https://emergency.cdc.gov/coca/calls/2020/USCDC_1052-DM28623. Accessed February 23, 2021.
47. Mamishi S, Movahedi Z, Mohammadi M, et al. Multisystem inflammatory syndrome associated with SARS-CoV-2 infection in 45 children: A first report from Iran. Epidemiol Infect 2020;148. https://doi.org/10.1017/S095026882000196X.
48. Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 2021. https://doi.org/10.1001/jama.2021.2091.
49. Gkoutzourelas A, Bogdanos DP, Sakkas LI. Kawasaki disease and COVID-19. Mediterr J Rheumatol 2020;31(Suppl 2):268. https://doi.org/10.31138/mjr.31.3.268.
50. Burgi Vieira C, Ferreira AT, Botelho Cardoso F, et al. Kawasaki-like syndrome as an emerging
complication of SARS-CoV-2 infection in young adults. Eur J Case Reports Intern Med 2020; 7(10):001886.

51. Hayran Y, Yorulmaz A, Gür G, et al. Different hair loss patterns in two pediatric patients with COVID-19-associated multisystem inflammatory syndrome in children. Dermatol Ther 2021. https://doi.org/10.1111/dth.14820.

52. Multisystem Inflammatory Syndrome in Children (MIS-C) Intermediate Guidance. Available at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/. Accessed January 17, 2021.

53. Cappel JA, Wetter DA. Clinical characteristics, etiologic associations, laboratory findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic, 2000 to 2011. Mayo Clin Proc 2014;89(2):207–15. https://doi.org/10.1016/j.mayocp.2013.09.020.

54. Perniosis - NORD (National Organization for Rare Disorders). Available at: https://rarediseases.org/rare-diseases/perniosis/. Accessed January 20, 2021.

55. Weston WL, Morelli JG. Childhood pernio and cryoproteins. Pediatr Dermatol 2000;17(2):97–9.

56. Tan SW, Tam YC, Oh CC. Skin manifestations of COVID-19: A worldwide review. JAAD Int 2021;2:119–33.

57. Recalcati S, Barbagallo T, Frasin LA, et al. Acral perniosis: Clinical features, histopathology, and relationship to COVID-19. Pediatr Dermatol 2020;37(3):419–23.

58. Le Cleach L, Dousset L, Assier H, et al. Most children with COVID-19 have asymptomatic acral perniosis: Clinical features, histopathology, and relationship to COVID-19. Pediatr Dermatol 2020;37(3):419–23.

59. Freeman EE, McMahon DE, Lipoff JB, et al. Perniosis-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries. J Am Acad Dermatol 2020;83(2):486–92.

60. Huang Y, Dai H, Ke R. Principles of effective and robust innate immune response to viral infections: A multiplex network analysis. Front Immunol 2019;10:1736.

61. Volpi S, Picco P, Caorsi R, et al. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol 2016;14(1). https://doi.org/10.1186/s12969-016-0094-4.

62. Trouillet-Assant S, Viel S, Gaymard A, et al. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol 2020;146(1):206–8.e2.

63. Kolivras A, Dehavay F, Delplace D, et al. Coronavirus (COVID-19) infection-induced chilblains: A case report with histopathologic findings. JAAD Case Rep 2020;6(6):489–92.

64. Damsky W, Peterson D, King B. When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection. J Am Acad Dermatol 2020;83(3):e269–70.

65. Hubiche T, Cardot-Leccia N, Le Duff F, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol 2020. https://doi.org/10.1001/jamadermatol.2020.4324.

66. Cordero KM, Reynolds SD, Wattier R, et al. Clustered cases of acral perniosis: Clinical features, histopathology, and relationship to COVID-19. Pediatr Dermatol 2020;37(3):419–23.

67. Mastrolonardo M, Romita P, Bonifazi E, et al. The management of the outbreak of acral skin manifestations in asymptomatic children during COVID-19 era. Dermatol Ther 2020;33(4). https://doi.org/10.1111/dth.13617.

68. Roca-Ginés J, Torres-Navarro I, Sánchez-Arráez J, et al. Assessment of acute acral lesions in a case series of children and adolescents during the COVID-19 pandemic. JAMA Dermatol 2020;156(9):992–7.

69. Docampo-Simón A, Sánchez-Pujol MJ, Juan-Carpena G, et al. Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review. J Eur Acad Dermatol Venereol 2020;34(9):e445–7.

70. Heymann WR. The Profound Dermatological Manifestations of COVID-19: Part IV - Cutaneous Features. American Academy of Dermatology Association, 2020. Available at: https://www.aad.org/dw/dw-insights-and-inquiries/2020-archive/april/dermatological-manifestations-covid-19-part-4. Accessed February 26, 2021.

71. Neri I, Virdi A, Corsini I, et al. Major cluster of paediatric ‘true’ primary chilblains during the COVID-19 pandemic: a consequence of lifestyle changes due to lockdown. J Eur Acad Dermatol Venereol 2020;34(11):2630–5.

72. Freeman EE, McMahon DE, Hruza GJ, et al. Timing of PCR and antibody testing in patients with COVID-19–associated dermatologic manifestations. J Am Acad Dermatol 2021;84(2):505–7.

73. El Hachem M, Diociaiuti A, Concato C, et al. A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection. J Eur Acad Dermatol Venereol 2020;34(11):2630–5.

74. Freeman EE, McMahon DE, Hruza GJ, et al. Timing of PCR and antibody testing in patients with COVID-19–associated dermatologic manifestations. J Am Acad Dermatol 2021;84(2):505–7.

75. El Hachem M, Diociaiuti A, Concato C, et al. A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection. J Eur Acad Dermatol Venereol 2020;34(11):2630–5.

76. Du Z, Zhu F, Guo F, et al. Detection of antibodies against SARS-CoV-2 in patients with COVID-19. J Med Virol 2020;92(10):1735–8.

77. Hu X, Xing Y, Jia J, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. Sci Total Environ 2020;728.
76. COVID-19 Serology Surveillance Strategy|CDC. Available at: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology-surveillance/index.html. Accessed January 28, 2021.

77. Freeman EE, McMahon DE, Fox LP. Emerging evidence of the direct association between COVID-19 and chilblains. JAMA Dermatol 2021;157(2). https://doi.org/10.1001/jamadermatol.2020.4937.

78. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. Lancet 2020;396(10259):1335–44.

79. Colmenero I, Santonja C, Alonso-Riaño M, et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol 2020;183(4):729–37.

80. Colonna C, Genovese G, Monzani NA, et al. Outbreak of chilblain-like acral lesions in children in the metropolitan area of Milan, Italy, during the COVID-19 pandemic. J Am Acad Dermatol 2020;83(3):965–9.

81. Promenzio L, Arcangeli F, Cortis E, et al. Erythema pernio-like in four adolescents in the era of the Coronavirus-2 infection. Rev Recent Clin Trials 2020;15. https://doi.org/10.1111/157488711566621016153031.

82. Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol 2020;34(7):e291–3.

83. García-Lara G, Linares-González L, Ródenas-Herranz T, et al. Chilblain-like lesions in pediatrics of coronavirus infection disease (COVID 2019). An Pediatría (Engl Ed) 2020;92(6):374–5.

84. Papa A, Salzano AM, Di Dato MT, et al. Images in practice: painful cutaneous vasculitis in a SARS-Cov-2 IgG-positive child. Pain Ther 2020;9(2):805–7.

85. Recalcati S, Barbagallo T, Tonolo S, et al. Relapse of chilblain-like lesions during the second wave of COVID-19. J Eur Acad Dermatol Venereol 2021. https://doi.org/10.1111/jdv.17168.

86. Torrelo A, Andina D, Santonja C, et al. Erythema multiforme-like lesions in children and COVID-19. Pediatr Dermatol 2020;37(3):442–6.

87. Garcia-Gil MF, Garcia Garcia M, Monte Serrano J, et al. Acral purpuric lesions (erythema multiforme type) associated with thrombotic vasculopathy in a child during the COVID-19 pandemic. J Eur Acad Dermatol Venereol 2020;34(9):e443–5.

88. Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, et al. Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol 2020;83(1):e61–3.

89. Mastrolonardo M, Romita P, Bonifazi E, et al. The management of the outbreak of acral skin manifestations in asymptomatic children during COVID-19. Dermatol Ther 2020;33(4). https://doi.org/10.1111/dth.13617.

90. Andina D, Colmenero I, Santonja C, et al. Suspected COVID-19-related reticulated purpura of the soles in an infant. Pediatr Dermatol 2020;pde:14409.

91. Garcia-Gil MF, Monte Serrano J, Lapeña-Casado A, et al. Livedo reticularis and acrocyanosis as late manifestations of COVID-19 in two cases with familial aggregation. Potential pathogenic role of complement (C4c). Int J Dermatol 2020;59(12):1549–51.

92. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020;34(5):e212–3.

93. Fertitta L, Welfringer-Morin A, Ouedrani A, et al. Immunological and virological profile of children with chilblain-like lesions and SARS-CoV-2. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16972.

94. Marzano AV, Genovese G, Fabbrocini G, et al. Vari-cellula-like exanthem as a specific COVID-19–associated skin manifestation: Multicenter case series of 22 patients. J Am Acad Dermatol 2020;83(1):280–5.

95. Morey-Olivé M, Espiau M, Mercadal-Hally M, et al. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019). An Pediatría (Engl Ed) 2020;92(6):374–5.

96. Schneider H, Adams O, Weiss C, et al. Clinical characteristics of children with viral single- and co-infections and a petechial rash. Pediatr Infect Dis J 2013;32(5):186–91.

97. Olisova OY, Anpilogova EM, Shnakhova LM. Cutaneous manifestations in COVID-19: A skin rash in a child. Dermatol Ther 2020;33(6):e13712.

98. Olisova OY, Anpilogova EM, Shnakhova LM. Cutaneous manifestations in COVID-19: A skin rash in a child. Dermatol Ther 2020;33(6). https://doi.org/10.1111/dth.13712.

99. Aghazadeh N, Homayouni M, Sartori-Valinotti JC. Oral vesicles and acral erythema: report of a cutaneous manifestation of COVID-19. Int J Dermatol 2020;59(9):1153–4.

100. Bursel Duramaz B, Yozgat CY, Yozgat Y, et al. Appearance of skin rash in pediatric patients with COVID-19: Three case presentations. Dermatol Ther 2020;33(4). https://doi.org/10.1111/dth.13594.

101. Kamali Aghdam M, Jafari N, Eftekhari K. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report. Infect Dis (Auckl) 2020;52(6):427–9.

102. de Miranda Henriques-Souza AM, de Melo ACMG, de Aguilar Coelho Silva Madeiro B, et al. Acute
disseminated encephalomyelitis in a COVID-19 pediatric patient. Neuroradiology 2020;63(1). https://doi.org/10.1007/s00234-020-02571-0.

103. Cao Q, Chen YC, Chen CL, et al. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. J Formos Med Assoc 2020;119(3):670–3.

104. Wang J, Li Y, Musch DC, et al. Progression of myopia in school-aged children after COVID-19 home confinement. JAMA Ophthalmol 2021. https://doi.org/10.1001/jamaophthalmol.2020.6239.

105. Michigan.gov. Children and COVID-19: State Data Report. 2021. Available at: https://www.michigan.gov/coronavirus/0,9753,7-406-98163_98173--,00.html. Accessed April 26, 2021.

106. Mass.gov. COVID-19 Response Reporting. 2021. Available at: https://www.mass.gov/info-details/covid-19-response-reporting. Accessed April 26, 2021.

107. HopkinsMedicine.org. New Variants of Coronavirus: What You Should Know. 2021. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/a-new-strain-of-coronavirus-what-you-should-know. Accessed April 26, 2021.

108. Jenco M. AAP helps pediatricians prepare to vaccinate children, adolescents against COVID-19. AAP News; 2021. Available at: https://www.aappublications.org/news/2021/04/08/covid-vaccine-children-aap-guidance-040821. Accessed April 26, 2021.

109. Gupta A, Gill A, Sharma M, et al. Multi-system inflammatory syndrome in a child mimicking Kawasaki disease. J Trop Pediatr 2020. https://doi.org/10.1093/tropicalmed/frm060.

110. Huang WC, Huang LM, Chang IS, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics 2009;123(3). https://doi.org/10.1542/peds.2008-2187.

111. Lin M-T, Wu M-H. The global epidemiology of Kawasaki disease: Review and future perspectives. Glob Cardiol Sci Pract 2018;2017(3). https://doi.org/10.21542/gcsp.2017.20.

112. Agarwal S, Agrawal DK. Kawasaki disease: etiopathogenesis and novel treatment strategies. Expert Rev Clin Immunol 2017;13(3):247–58.

113. Baker AL, Lu M, Minich LLA, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr 2009;154(4). https://doi.org/10.1016/j.jpeds.2008.10.006.

114. Taddio A, Rossi ED, Monasta L, et al. Describing Kawasaki shock syndrome: results from a retrospective study and literature review. Clin Rheumatol 2017;36(1):223–8.

115. Rosés-Gibert P, Gimeno Castillo J, Saenz Aguirre A, et al. Acral lesions in a pediatric population during the COVID-19 pandemic: a case series of 36 patients from a single hospital in Spain. World J Pediatr 2020;16(6):629–32.

116. Gallizzi R, Sutera D, Spagnolo A, et al. Management of pernio-like cutaneous manifestations in children during the outbreak of COVID-19. Derma Ther 2020;33(6). https://doi.org/10.1111/dth.14312.

117. Andina D, Noguer-Morel L, Bascuas-Arribas M, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol 2020;37(3):406–11.

118. Maniaci A, Iannella G, Vicini C, et al. A case of covid-19 with late-onset rash and transient loss of taste and smell in a 15-year-old boy. Am J Case Rep 2020;21:1–6.

119. Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine 2020;26. https://doi.org/10.1016/j.eclinm.2020.100527.